Anticancer agent pristimerin inhibits IL-2 induced activation of T lymphocytes

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Pristimerin (PM) is a triterpenoid with known cytotoxic effects on cancer cells.
• The impact of PM on T lymphocyte activation, vital for anti-tumor immunity, remains unexplored.
• Interleukin-2 (IL-2) is critical for T cell activation and the development of anti-tumor immune responses.

Purpose of the Study:

• To investigate the effect of PM on IL-2-induced T cell proliferation.
• To assess PM's influence on lymphokine-activated killer (LAK) cell generation.
• To elucidate the signaling pathways affected by PM during IL-2-mediated T cell activation.

Main Methods:

• Mouse splenic T cells were treated with IL-2 and varying concentrations of PM.
• T cell proliferation and LAK cell generation were quantified.
• Key signaling pathways, including Jak/STAT, Erk1/2, and downstream gene products, were analyzed.

Main Results:

• PM significantly inhibited IL-2-induced T cell proliferation and LAK cell generation at low concentrations.
• PM suppressed the activation of Janus kinase/signal transducers and activators of transcription (Jak/STAT) and extracellular signal-regulated kinase 1 and 2 (Erk1/2) pathways.
• PM also inhibited the expression of proliferation markers (p-c-fos, p-c-jun, c-myc, cyclin D1) and prosurvival pathways (NF-κB, p-Akt, p-mTOR).

Conclusions:

• Pristimerin effectively inhibits IL-2-induced T cell activation and LAK cell generation.
• PM disrupts multiple IL-2-mediated signaling cascades, including Jak/STAT, Erk1/2, and prosurvival pathways.
• These findings suggest PM has immunomodulatory properties impacting T cell-mediated anti-tumor immunity.